These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29520365)

  • 1. Platelet-Targeted Gene Therapy for Hemophilia.
    Shi Q
    Mol Ther Methods Clin Dev; 2018 Jun; 9():100-108. PubMed ID: 29520365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
    Cai Y; Shi Q
    Front Immunol; 2020; 11():964. PubMed ID: 32595633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF.
    Shi Q; Wilcox DA; Fahs SA; Kroner PA; Montgomery RR
    Mol Genet Metab; 2003 May; 79(1):25-33. PubMed ID: 12765843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
    Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
    J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors.
    Miao CH
    Thromb J; 2016; 14(Suppl 1):41. PubMed ID: 27766066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
    Kiouptsi K; Reinhardt C
    Subcell Biochem; 2020; 94():437-464. PubMed ID: 32189311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.
    Du LM; Nurden P; Nurden AT; Nichols TC; Bellinger DA; Jensen ES; Haberichter SL; Merricks E; Raymer RA; Fang J; Koukouritaki SB; Jacobi PM; Hawkins TB; Cornetta K; Shi Q; Wilcox DA
    Nat Commun; 2013; 4():2773. PubMed ID: 24253479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
    Li X; Gabriel DA
    Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond.
    Kumar S; Schroeder JA; Shi Q
    J Thromb Haemost; 2024 Jan; 22(1):23-34. PubMed ID: 37558132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
    Kao KJ; Pizzo SV; McKee PA
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
    Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
    J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular trafficking of factor VIII to von Willebrand factor storage granules.
    Rosenberg JB; Foster PA; Kaufman RJ; Vokac EA; Moussalli M; Kroner PA; Montgomery RR
    J Clin Invest; 1998 Feb; 101(3):613-24. PubMed ID: 9449695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The physiology and pathophysiology of the factor VIII complex.
    Hamer RJ; Houdijk WP; Sixma JJ
    Crit Rev Oncol Hematol; 1986; 6(1):19-54. PubMed ID: 3096583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets and hemophilia: A review of the literature.
    Riedl J; Ay C; Pabinger I
    Thromb Res; 2017 Jul; 155():131-139. PubMed ID: 28550758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
    Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.